Learn how to craft stunning mixed media paper VFX in Adobe Premiere Pro with this step-by-step tutorial. This guide shows how to combine textures, layers, and effects to achieve professional-quality ...

Pfizer reported fourth-quarter revenue and earnings that topped estimates even amid dwindling demand for its Covid products. The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled ...

Pfizer said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. The data offer early evidence that the injection can ...

Pfizer (PFE) announced on Tuesday that a mid-stage trial evaluating a monthly maintenance dosing regimen of its experimental obesity drug indicated that the GLP-1 receptor agonist PF’3944 (MET-097i) ...

Priovant Therapeutics, a company established in 2021 as part of a transaction between Pfizer (PFE) and Roivant Sciences (ROIV), announced positive mid-stage trial results for its lead asset, ...

Patients in a phase 2b trial kept losing weight after switching to monthly dosing of Pfizer’s GLP-1 receptor agonist, providing early validation of the drugmaker’s $10 billion bet on Metsera. The ...

That's the good news. The bad news is that while Pfizer "beat" on both sales and adjusted earnings, its earnings as calculated according to generally accepted accounting principles (GAAP) showed a ...

The settlement will have Pfizer walking away with $29 million from the $602 million settlement that was distributed to victims of a insider trading scheme involving a unit of billionaire Steven ...

Pfizer’s stock closed 3% lower on Tuesday after investors were disappointed by limited midstage trial data for the weight-loss drug it acquired as part of a contested $10 billion acquisition. The ...

To stir up support for the fight against cancer, Pfizer has turned to one of the most iconic pep talks of all time. A new ad debuting on Wednesday’s World Cancer Day borrows several snippets from the ...

Pfizer released data from the Phase 2b VESPER-3 study of monthly maintenance dosing of PF'3944 (MET-097i) in adults with obesity or overweight without type 2 diabetes. The U.S. drug giant added the ...